2024
Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor
Malik S, Pradeep S, Kumar V, Xiao Y, Deng Y, Fan R, Vasquez J, Singh V, Bahal R. Antitumor efficacy of a sequence-specific DNA-targeted γPNA-based c-Myc inhibitor. Cell Reports Medicine 2024, 5: 101354. PMID: 38183981, PMCID: PMC10829792, DOI: 10.1016/j.xcrm.2023.101354.Peer-Reviewed Original ResearchConceptsTarget genomic DNAGenomic DNASequencing of genomic DNAGenomic DNA levelInhibit c-myc transcriptionC-myc transcriptionGenomic DNA targetsTarget oncogenesMultiple cell linesC-Myc inhibitorCancer therapyHistone deacetylase inhibitorsRNA targetsDNA targetsPatient-derived xenograftsPre-clinical modelsDNADeacetylase inhibitorsCell linesOncogeneInhibiting oncogenesDNA levelsAntitumor efficacyPrecision medicineChemotherapeutic drugs
2023
Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors
Xu S, Campbell A, Chiang V, Bindra R, Vasquez J, Pashankar F. Use of stereotactic radiosurgery in treatment of brain metastases from pediatric extracranial solid tumors. Pediatric Blood & Cancer 2023, 70: e30303. PMID: 36975152, DOI: 10.1002/pbc.30303.Peer-Reviewed Original ResearchRhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
Vasquez J, Luo L, Hiniker S, Rhee D, Dasgupta R, Chen S, Weigel B, Xue W, Venkatramani R, Arndt C. Rhabdomyosarcoma with isolated lung metastases: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatric Blood & Cancer 2023, 70: e30293. PMID: 36916768, PMCID: PMC10424503, DOI: 10.1002/pbc.30293.Peer-Reviewed Original ResearchConceptsEvent-free survivalMetastatic diseaseYears of ageOverall survivalOncology GroupLung metastasesExact testSoft Tissue Sarcoma CommitteeSuperior event-free survivalBetter survival outcomesKaplan-Meier methodChildren's Oncology GroupRisk stratification algorithmLog-rank testOutcome of childrenFisher's exact testN0 diseaseAggressive treatmentMetastatic rhabdomyosarcomaExtrapulmonary sitesMetastatic sitesExtremity tumorsSurvival outcomesEmbryonal histologyCOG protocols
2022
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options In Oncology 2022, 23: 1566-1589. PMID: 36242713, DOI: 10.1007/s11864-022-01024-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHomologous recombination deficiencyPrimary CNS tumorsCNS tumorsClinical trialsPARP inhibitorsPreclinical evidencePrimary malignant central nervous system tumorMalignant central nervous system tumorsCentral nervous system tumorsImmune checkpoint inhibitorsStandard treatment modalityInitial clinical trialsEarly phase trialsNervous system tumorsCentral nervous tumorsExtracranial cancerCheckpoint inhibitorsDevastating malignancyStandard therapyOngoing trialsCombination therapyTreatment optionsTreatment modalitiesSystem tumorsPhase trialsMetastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide
Singh C, Bindra RS, Glazer PM, Vasquez JC, Pashankar F. Metastatic and multiply relapsed SDH‐deficient GIST and paraganglioma displays clinical response to combined poly ADP‐ribose polymerase inhibition and temozolomide. Pediatric Blood & Cancer 2022, 70: e30020. PMID: 36151992, DOI: 10.1002/pbc.30020.Peer-Reviewed Original ResearchTargeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy
Ueno D, Vasquez JC, Sule A, Liang J, van Doorn J, Sundaram R, Friedman S, Caliliw R, Ohtake S, Bao X, Li J, Ye H, Boyd K, Huang RR, Dodson J, Boutros P, Bindra RS, Shuch B. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget 2022, 13: 1054-1067. PMID: 36128328, PMCID: PMC9477221, DOI: 10.18632/oncotarget.28273.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine Diphosphate RiboseAnimalsCarcinoma, Renal CellCitric Acid CycleDioxygenasesDNAFumarate HydrataseFumaratesHumansJumonji Domain-Containing Histone DemethylasesKidney NeoplasmsLysineMicePoly (ADP-Ribose) Polymerase-1Poly(ADP-ribose) Polymerase InhibitorsSuccinate DehydrogenaseSuccinatesTemozolomideConceptsRenal cell carcinomaPoly ADP-ribose polymerase inhibitorsADP-ribose polymerase inhibitorsCell carcinomaSDH-deficient renal cell carcinomaPolymerase inhibitorsLow-dose temozolomideAggressive renal cell carcinomaHereditary cancer syndromesNovel therapeutic strategiesDeficient murine modelStandard dosingTMZ resultsMurine modelTherapeutic strategiesCombination treatmentCancer syndromesTumor growthHomologous recombination DNA repair pathwayAccumulation of fumarateHR deficiencyPARP inhibitionTemozolomideChemotherapyCarcinomaTOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y. TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor. Molecular Cancer Therapeutics 2022, 21: 1090-1102. PMID: 35439320, PMCID: PMC9256811, DOI: 10.1158/1535-7163.mct-21-1000.Peer-Reviewed Original ResearchConceptsATR inhibitorsTop1 inhibitorsHomologous recombination deficiencyNovel molecular interactionApoptotic cell deathCancer cellsTop1 cleavage complexesAtaxia telangiectasiaCleavage complexesCell deathDNA damageHigher DNA damageMolecular interactionsDNA baseKinase inhibitorsI inhibitorMolecular pharmacologyMouse xenograftsTOP1Recombination deficiencyTopoisomerase I inhibitorInhibitorsTumor growthRad3Predictive biomarkers
2020
Risk associated alterations in marrow T cells in pediatric leukemia
Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim H, Duffy A, Doxie D, Kaushal A, Foster C, DeRyckere D, Castellino S, Kemp ML, Qiu P, Dhodapkar M, Dhodapkar K. Risk associated alterations in marrow T cells in pediatric leukemia. JCI Insight 2020, 5: e140179. PMID: 32692727, PMCID: PMC7455136, DOI: 10.1172/jci.insight.140179.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone MarrowCase-Control StudiesChildChild, PreschoolFemaleGene Expression ProfilingHumansInfantKiller Cells, NaturalLeukemia, Myeloid, AcuteMalePrecursor Cell Lymphoblastic Leukemia-LymphomaReproducibility of ResultsRisk FactorsSingle-Cell AnalysisT-LymphocytesTumor MicroenvironmentConceptsAcute lymphoblastic leukemiaNaive T cellsT cellsDisease riskChildhood leukemiaLymphoblastic leukemiaStem-like memory T cellsTerminal effector T cellsB-cell acute lymphoblastic leukemiaChronic immune activationCell acute lymphoblastic leukemiaEffector T cellsMarrow T cellsMemory T cellsAcute myelogenous leukemiaEvidence of dysfunctionStem-like genesImmune signaturesNK cellsClinical featuresImmune environmentImmune landscapeImmune therapyImmune activationImmune microenvironmentSubtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma
Robinson MH, Vasquez J, Kaushal A, MacDonald TJ, Vega J, Schniederjan M, Dhodapkar K. Subtype and grade-dependent spatial heterogeneity of T-cell infiltration in pediatric glioma. Journal For ImmunoTherapy Of Cancer 2020, 8: e001066. PMID: 32788236, PMCID: PMC7422651, DOI: 10.1136/jitc-2020-001066.Peer-Reviewed Original ResearchConceptsT cell infiltrationHigh-grade gliomasT-cell densityLow-grade tumorsT cellsGlial tumorsTissue-resident memory T cellsTumor-resident T cellsPediatric gliomasTumor-infiltrating T cellsMemory T cellsCancer-related mortalityPediatric glial tumorsSingle-cell mass cytometryExpression of SOX2Stem cell markersImmune controlImmune therapyRecurrent tumorsImmune cellsImmunofluorescence immunohistochemistryPleomorphic xanthoastrocytomaBrain tumorsImmune architectureAdult gliomas
2017
SOX2 immunity and tissue resident memory in children and young adults with glioma
Vasquez JC, Huttner A, Zhang L, Marks A, Chan A, Baehring JM, Kahle KT, Dhodapkar KM. SOX2 immunity and tissue resident memory in children and young adults with glioma. Journal Of Neuro-Oncology 2017, 134: 41-53. PMID: 28620836, PMCID: PMC7906294, DOI: 10.1007/s11060-017-2515-8.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAntigen-Presenting CellsB7-H1 AntigenBrain NeoplasmsCell ProliferationChildChild, PreschoolCytokinesFemaleFlow CytometryGliomaHumansInfantMaleMyeloid CellsProgrammed Cell Death 1 ReceptorReceptors, ImmunologicRNA, Small InterferingSOXB1 Transcription FactorsT-LymphocytesTransfectionYoung AdultConceptsPediatric glial tumorsGlial tumorsT cellsExpression of SOX2Inhibitory checkpointsCD8/CD4 T cellsTissue-resident memory phenotypeTumor-infiltrating immune cellsTumor-infiltrating T cellsTumor cellsYoung adultsResident memory phenotypeTissue-resident memoryAnti-tumor immunityT cell immunityCD4 T cellsNatural killer cellsGlial tumor cellsNew antigenic targetsSingle-cell mass cytometryHigh mutation burdenStem cell antigenGlioma initiating cellsImmune checkpointsPD-1
2016
ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells
Boddupalli CS, Nair S, Gray SM, Nowyhed HN, Verma R, Gibson JA, Abraham C, Narayan D, Vasquez J, Hedrick CC, Flavell RA, Dhodapkar KM, Kaech SM, Dhodapkar MV. ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. Journal Of Clinical Investigation 2016, 126: 3905-3916. PMID: 27617863, PMCID: PMC5096804, DOI: 10.1172/jci85329.Peer-Reviewed Original ResearchConceptsTissue-resident memory T cellsMemory T cellsT cellsTRM cellsCellular therapyAdoptive cellular therapyImmune-deficient micePotential cellular therapySP T cellsSide population cellsHuman T cellsPutative subsetsAdoptive transferDistinct gene expression profilesCell mobilizationImmune surveillanceQuiescent subsetPopulation cellsMiceTherapyQuiescent phenotypeDistinct subsetsMember 1Nuclear receptorsSignature genes
2015
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets
Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, Vasquez J, Koduru S, Ren Y, Wang M, Couto S, Breider M, Hansel D, Seropian S, Cooper D, Thakurta A, Yao X, Dhodapkar KM, Dhodapkar MV. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood 2015, 125: 4042-4051. PMID: 25869284, PMCID: PMC4481593, DOI: 10.1182/blood-2014-11-611426.Peer-Reviewed Original ResearchConceptsImmune activationAntitumor effectsNK cellsT cellsMore frequent adverse eventsClinical antitumor effectsFrequent adverse eventsNatural killer cellsIntermittent dosing strategyDirect antitumor effectsExpression of cytokinesT cell activationGreater tumor reductionPomalidomide/Coinhibitory receptorsAdverse eventsClinical responseOverall survivalKiller cellsPharmacodynamic effectsImmunomodulatory effectsMultiple myelomaTumor reductionIntermittent dosingPharmacodynamic analysis